The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)


Stanford Reference:

97-168


Abstract


Researchers in Michele Calos' lab have developed a patented method to provide site-specific integration of genes of interest into the chromosomes of target cells. The method uses a recombinase enzyme to mediate integration of incoming DNA into inserted or pre-existing target sites in the chromosomes. The integration frequency in human and mouse cells is higher than that of homologous recombination or random integration. Integration may occur predominantly at a low number of positions. The method applies to various higher eukaryotic species and can be used in combination with most gene delivery methods.

Applications


  • Construction of transgenic animals and plants
  • Rapid construction of cell lines for protein production
  • Modification of cells, tissues, and organs, for a variety of uses

Advantages


  • If the method is applied to pre-existing target sites in the genome, it is not necessary to first insert the target site.
  • Integration frequency is higher than the frequency of homologous recombination or random integration.
  • Because integration is carried out by a recombinase enzyme with defined specificity, integration is more site specific than the random integration typical of most current gene introduction methods.

Publications



Calos Lab Web Page


www.stanford.edu/~calos/

Innovators & Portfolio



Patent Status



Date Released

 5/11/2000
 

Licensing Contact


Ximena Ares, Licensing Associate
650-724-0960 (Direct)
Login to Request Information

78-017 Monoclonal Antibodies: 11-6 anti-Ig-5b, 11-5 anti-I-A (2), 11-4 anti-H-2Kk, 11-3 anti-I-A917), 10-4 anti-Ig-5a, H-12 anti-THY 1.2
82-008 A Monoclonal Antibody Specific For Mouse Granulocytes
82-010 A Monoclonal Antibody Specific for the B-220 Surface Glycoprotein in Mouse (RA3-3A1)

more technologies

Related Keywords


therapeutic: gene therapy   research tool   therapeutic   
 

   

  

Also of Interest...
78-017 Monoclonal Antibodies: 11-6 anti-Ig-5b, 11-5 anti-I-A (2), 11-4 anti-H-2Kk, 11-3 anti-I-A917), 10-4 anti-Ig-5a, H-12 anti-THY 1.2
82-008 A Monoclonal Antibody Specific For Mouse Granulocytes
82-010 A Monoclonal Antibody Specific for the B-220 Surface Glycoprotein in Mouse (RA3-3A1)

Recently Viewed...
S97-168 Recombinase-Mediated Site Specific Integration ("Wildtype" recombinases)